Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Fig. 2

CONSORT Flow Diagram. The reason “Adverse event” includes both inacceptable toxicity and (serious) adverse event. A therapy was considered completed if the reason for end of treatment was either progressive disease or death. Follow-up was considered completed if the follow-up was started and the reason for end of study was death. For two patients, “death” was documented as the reason for end of treatment in second-line therapy, although the death occurred later than 30 days after end of treatment (safety follow-up period). EOT = end of treatment; EOS = end of study; IC = informed consent

Back to article page
\